Antares Pharma Inc (ATRS):財務・戦略的SWOT分析

GlobalDataが発行した調査報告書(GDPH3783FSA)
◆英語タイトル:Antares Pharma Inc (ATRS) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH3783FSA
◆発行会社(リサーチ会社):GlobalData
◆発行日:2021年3月
◆ページ数:53
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:United States
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Antares Pharma Inc (ATRS) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Antares Pharma Inc (Antares Pharma) is a specialty pharmaceutical company that develops, manufactures, and commercializes self-administered parenteral pharmaceutical products and technologies. The company’s portfolio encompasses novel therapeutic products for the treatment of polyarticular juvenile idiopathic arthritis, adults with severe rheumatoid arthritis, severe recalcitrant psoriasis, migraine and cluster headache, and to reduce the risk of preterm birth in pregnant women. It caters its subcutaneous injection technology platforms to both generic and branded injectables. Antares Pharma’s injectables are available in disposable multi-dose pen injectors and unit dose containers. The company employs drug delivery systems to advance drug compounds and drug delivery methods. It also focuses on product development programs in partnership with various leading pharmaceutical companies including Teva and AMAG. The company has a presence in the US and Switzerland. Antares Pharma is headquartered in Ewing, New Jersey, the US.

Antares Pharma Inc Key Recent Developments

Mar 02,2021: Antares Pharma reports fourth quarter and full-year 2020 financial and operating results
Jan 11,2021: Antares Pharma announces full-year 2021 revenue guidance of $175-200 million
Nov 05,2020: Antares Pharma reports strong third quarter 2020 financial and operating results
Aug 10,2020: Antares Pharma appoints Tram Bui as vice president of corporate communications and investor relations
Aug 06,2020: Antares Pharma reports strong second quarter 2020 operating and financial results; reinstates full-year 2020 revenue guidance

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Antares Pharma Inc – Key Facts
Antares Pharma Inc – Key Employees
Antares Pharma Inc – Key Employee Biographies
Antares Pharma Inc – Major Products and Services
Antares Pharma Inc – History
Antares Pharma Inc – Company Statement
Antares Pharma Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Antares Pharma Inc – Business Description
Business Segment: Licensing and Development
Performance
Business Segment: Product Sales
Performance
Business Segment: Royalties
Performance
Geographical Segment: Europe
Performance
Geographical Segment: Other
Performance
Geographical Segment: The US
Performance
R&D Overview
Antares Pharma Inc – Corporate Strategy
Antares Pharma Inc – SWOT Analysis
SWOT Analysis – Overview
Antares Pharma Inc – Strengths
Antares Pharma Inc – Weaknesses
Antares Pharma Inc – Opportunities
Antares Pharma Inc – Threats
Antares Pharma Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Antares Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Antares Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Antares Pharma Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 02, 2021: Antares Pharma reports fourth quarter and full-year 2020 financial and operating results
Jan 11, 2021: Antares Pharma announces full-year 2021 revenue guidance of $175-200 million
Nov 05, 2020: Antares Pharma reports strong third quarter 2020 financial and operating results
Aug 10, 2020: Antares Pharma appoints Tram Bui as vice president of corporate communications and investor relations
Aug 06, 2020: Antares Pharma reports strong second quarter 2020 operating and financial results; reinstates full-year 2020 revenue guidance
Jul 20, 2020: Antares Pharma appoints Patrick Shea senior vice president of commercial
May 05, 2020: Antares Pharma reports first quarter 2020 operating and financial results
Mar 03, 2020: Antares Pharma reports fourth quarter and full year 2019 operating and financial results
Jan 27, 2020: Antares Pharma announces full-year 2020 net revenue guidance range of $135 to $155 million
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Antares Pharma Inc, Key Facts
Antares Pharma Inc, Key Employees
Antares Pharma Inc, Key Employee Biographies
Antares Pharma Inc, Major Products and Services
Antares Pharma Inc, History
Antares Pharma Inc, Other Locations
Antares Pharma Inc, Subsidiaries
Antares Pharma Inc, Key Competitors
Antares Pharma Inc, Ratios based on current share price
Antares Pharma Inc, Annual Ratios
Antares Pharma Inc, Annual Ratios (Cont...1)
Antares Pharma Inc, Annual Ratios (Cont...2)
Antares Pharma Inc, Interim Ratios
Antares Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Antares Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Antares Pharma Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Antares Pharma Inc (ATRS):財務・戦略的SWOT分析(Antares Pharma Inc (ATRS) - Financial and Strategic SWOT Analysis Review)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆